Carcinoma, Squamous Cell Clinical Trial
Official title:
Multi-centre, Open-label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)
The purpose of this study is to determine whether the topical application of PEP005 is safe and effective for the treatment of cutaneous squamous cell carcinoma in situ (SCCIS, Bowen's disease).
Status | Completed |
Enrollment | 24 |
Est. completion date | December 2006 |
Est. primary completion date | December 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male patients, at least 18 years of age. 2. Post-menopausal female patients, at least 18 years of age, i.e. no menses for at least 12 consecutive months, or without a uterus. 3. A primary, clinically diagnosed and histologically confirmed SCCIS lesion with the histological diagnosis being made within 90 days of the screening visit. 4. Longest diameter of the SCCIS lesion between 5 mm and 20 mm. 5. Ability to follow study instructions and likely to complete all study requirements. 6. Written informed consent has been obtained. 7. Written consent for tissue from the biopsy of the histologically confirmed SCCIS lesion to be examined and stored by the central dermatopathologist has been obtained. 8. Agreement from the patient to allow photographs of the selected SCCIS treatment area (including the face) to be used as part of the study data package. Exclusion Criteria: 1. Females of childbearing potential (a female is considered of childbearing potential unless she is post-menopausal, i.e. no menses for at least 12 consecutive months, or is without a uterus). 2. Location of the selected SCCIS lesion: 1. within 5 cm of an incompletely healed wound 2. within 2 cm of an eye, nose, or ear 3. within 1 cm of a scar 4. on the scalp, digits, lips, hands, feet, or ano-genital region 3. SCCIS lesions that have atypical clinical appearance, e.g. hypertrophic or hyperkeratotic or pigmented or ulcerated. 4. Histological evidence of nodular basal cell carcinoma (nBCC), superficial basal cell carcinoma (sBCC) or invasive squamous cell carcinoma (SCC) of the SCCIS in the biopsy sample. 5. Presence of suspected basal cell carcinoma (BCC) or invasive squamous cell carcinoma (SCC) within 2 cm of the selected SCCIS lesion. 6. Presence of known or suspected metastatic disease. 7. History or evidence of skin conditions other than SCCIS that would interfere with evaluation of the study medication (e.g. eczema, unstable psoriasis, xeroderma pigmentosa). 8. Known sensitivity to any of the ingredients in the study medication. 9. A cosmetic or therapeutic procedure (e.g. use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) 1. of the selected SCCIS lesion at any time; or 2. within 2 cm of the selected SCCIS lesion during the 4 weeks prior to screening visit; or 3. anticipated treatment within 10 cm of the selected SCCIS lesion during the study. 10. Treatment with 5-fluorouracil, imiquimod, diclofenac, or masoprocol - of the selected SCCIS lesion at any time; or - within 2 cm of the selected SCCIS lesion during the 6 months prior to study entry; or - anywhere during the 4 weeks prior to study entry; or - anticipated treatment anywhere during the study. 11. Treatment with photodynamic therapy - of the selected SCCIS lesion at any time; or - within 10 cm of the selected SCCIS lesion during the 6 months prior to study entry; or - anticipated treatment within 10 cm of the selected SCCIS lesion during the study. 12. Treatment with ionising radiation - of the selected SCCIS lesion at any time; or - within 2 cm of the selected SCCIS lesion prior to study entry; or - anticipated treatment anywhere during the study. 13. Treatment with other immunomodulators (e.g. vinblastine, podophyllin, colhamin, camptothecin), cytotoxic drugs (e.g. cyclophosphamide, azathioprine, chlorambucil, nitrogen mustard, methotrexate), or interferon/interferon inducers (other than imiquimod) - within 4 weeks prior to study entry; or - anticipated treatment during the study. 14. Use of acid-containing therapeutic products (e.g. salicylic acids or fruit acids, such as a and ß hydroxy acids and glycolic acids), topical retinoids, or light chemical peels - of the selected SCCIS lesion at any time; or - within 2 cm of the selected SCCIS lesion during the 4 weeks prior to study entry; or - anticipated treatment within 2 cm of the selected SCCIS lesion during the study. 15. Treatment with psoralen plus ultraviolet light A [UVA] (PUVA) or use of ultraviolet light B (UVB) therapy - of the selected SCCIS lesion at any time; or - anywhere during the 6 months prior to study entry; or - anticipated treatment anywhere during the study. 16. Use of systemic retinoids (e.g. isotretinoin, acitretin, bexarotene) - during the 6 months prior to study entry; or - anticipated treatment during the study. 17. Anticipated excessive or prolonged exposure to ultraviolet light (e.g. sunlight, tanning beds) or use of topical salves or topical steroids to the selected SCCIS lesion during the study. 18. SCCIS lesions requiring Mohs micrographic surgery. 19. Anticipated need for inpatient hospitalisation or inpatient surgery during the study. 20. Concurrent disease that suppresses the immune system (e.g. HIV, hepatitis) or uncontrolled systemic disease (e.g. uncontrolled hypertension, poorly controlled diabetes). 21. Use of medications that suppress the immune system (e.g. cyclosporine, prednisone, methotrexate, alefacept, infliximab) - within 4 weeks prior to study entry; or - anticipated treatment during the study. 22. Current evidence of chronic alcohol or drug abuse. 23. Current enrolment in an investigational drug or device study or participation in such a study within 30 days of entry into this study. 24. Entry into another investigational drug or device study while enrolled in this study. 25. A condition or situation which in the Investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study. 26. Selected SCCIS lesion within 5 cm of an area previously treated with PEP005. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | The Skin Centre | Benowa | Queensland |
Australia | Siller Medical | Brisbane | Queensland |
Australia | Southderm Pty Ltd | Kogarah | New South Wales |
Lead Sponsor | Collaborator |
---|---|
Peplin |
Australia,
Rosen R, Freeman M, Siller G, Zibert JR, Katsamas J, Knudsen KM, Spelman L. Ingenol mebutate 0.05% gel reduces cancer cells in squamous cell carcinoma in situ and shows marginal effect in seborrheic keratosis. JDDG J German Soc Dermatol 2013; 11(Suppl. 7)
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety | |||
Secondary | Efficacy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02743832 -
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT00389727 -
Simultaneous Integrated Boost (SIB)- IMRT
|
Phase 2 | |
Recruiting |
NCT02328391 -
STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE
|
N/A | |
Completed |
NCT00534950 -
Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
|
N/A | |
Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01362127 -
Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia
|
Phase 2 | |
Completed |
NCT00240682 -
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
|
Phase 2 | |
Terminated |
NCT02254044 -
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
|
Phase 1 | |
Active, not recruiting |
NCT00829192 -
Phase II AK Study in Organ Transplant Patients
|
Phase 2 | |
Completed |
NCT00539630 -
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
|
Phase 3 | |
Completed |
NCT00313027 -
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
|
N/A | |
Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
Not yet recruiting |
NCT06094829 -
Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
|
||
Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
Active, not recruiting |
NCT02664935 -
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 |